CK20 IHC

This test measures the presence of cytokeratin 20 (CK20) in tissue samples and helps identify bladder cancer and tumors of lower gastrointestinal tract.

The CK20 test is done for multiple purposes, including:

• Narrowing down the differential diagnosis of multiorgan carcinomas
• Providing important information for treatment planning and management
• Aiding in monitoring the effectiveness of treatment for multiorgan carcinomas.
• Assisting in the early detection and prevention of cancer

• The test may be recommended when there is suspicion of bladder cancer or tumors in the lower GI tract
• Individuals with symptoms such as blood in the urine (hematuria), changes in bowel habits, or other concerning signs may undergo this test
• To provide additional information for treatment planning and management
• To assess the response to treatment
• As part of routine screening for individuals at high risk of developing cancer

Abnormal results, indicating elevated levels of CK20, may suggest the presence of bladder cancer or tumors in the lower GI tract. It is important to discuss the test results with your doctor, who will interpret them in the context of your medical history and other diagnostic tests.

• A small tissue sample is collected from the affected area or organ.
• The sample is then processed and stained in the laboratory.
• The stained sample is examined under a microscope to measure the levels of CK20 protein.
• The results are reported to your doctor for further analysis and interpretation.

• Ensure you have the necessary tissue samples (paraffin blocks) along with the original histopathology report and relevant clinical and radiological details.
• Follow any specific instructions provided by your doctor regarding fasting or medication.

• Additional immunohistochemical markers to further characterise the tumour
• Molecular tests to identify specific genetic mutations related to multiorgan carcinomas
• Radiological imaging tests like CT scans or MRI to assess the extent of the disease

• Immunohistochemistry for Cytokeratin 20
• Immunohistochemistry with CK20 staining

Tumors in the lower gastrointestinal (GI) tract refer to abnormal growths or masses that develop in the organs of the digestive system located in the lower part of the abdomen. The lower GI tract includes the following organs:

• Colon: The colon, also known as the large intestine, is a major part of the lower GI tract. Tumors in the colon can be benign (non-cancerous) or malignant (cancerous). Colorectal cancer is a common type of malignancy that can originate in the colon.
• Rectum: The rectum is the final portion of the colon, and tumors can develop in this area. Rectal tumors may be benign or malignant and can present similar challenges to those arising in the colon.
• Anus: Tumors can also occur in the anus, which is the opening at the end of the digestive tract through which stool leaves the body. These tumors can be benign, such as anal warts, or malignant, like anal cancer.